CLB on NYSE
Logo: The logo is from the following website: https://www.corelab.com/ http://ewb.tamu.edu/getinvolved, Non-free logo, via Wikipedia5
American service Provider
Core Laboratories Inc ("Core Lab") is an American service provider of core and fluid analysis in the petroleum industry. Established in 1936, Core Lab is a global provider of proprietary and patented reservoir description and production enhancement services and products for the oil and gas industry.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 19, 2026.
Compare with WaterBridge Infrastructure LLC, Ranger Energy Services, Inc. or Nine Energy Service, Inc., or pick any stock.
See how the biggest companies compare on our leaderboards
Core Laboratories Inc ("Core Lab") is an American service provider of core and fluid analysis in the petroleum industry. Established in 1936, Core Lab is a global provider of proprietary and patented reservoir description and production enhancement services and products for the oil and gas industry.3
From the company’s reports to the SEC. Every number links to the filing it came from.
Revenue by product, business segment and region, as the company reports it to the SEC.
Service brought in 76% of the revenue Core Laboratories broke down this way in fiscal 2025.
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Service | $371.9M | $388.2M | $399.4M |
| Product | $137.9M | $135.6M | $127.1M |
Operating Segment Reservoir Description brought in 66% of the revenue Core Laboratories broke down this way in fiscal 2025.
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Segment Reservoir Description | $333.3M | $346.1M | $347.7M |
| Operating Segment Production Enhancement | $176.4M | $177.7M | $178.8M |
Outside the United States brought in 67% of the revenue Core Laboratories broke down this way in fiscal 2025.
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Outside the United States | $331.2M | $345.0M | $351.2M |
| United States | $178.5M | $178.9M | $175.3M |
Out of $526.5M in revenue.8
Out of $37.0M of cash from operations.8
Every line of the income statement as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $526.5M | $523.8M | $509.8M |
| General and administrative expense, exclusive of depreciation expense shown below | $45.4M | $39.8M | $40.3M |
| Depreciation | $14.3M | $14.4M | $15.3M |
| Amortization | $359.0K | $504.0K | $490.0K |
| Other (income) expense, net | -$7.6M | -$10.0M | -$850.0K |
| OPERATING INCOME | $56.5M | $58.6M | $54.6M |
| Interest expense | $10.6M | $12.4M | $13.4M |
| Income before income taxes | $45.9M | $46.2M | $41.2M |
| Income tax expense | $15.5M | $14.0M | $4.2M |
| Net income | $30.4M | $32.2M | $37.0M |
| Net income attributable to non-controlling interest | $722.0K | $753.0K | $350.0K |
| Net income attributable to Core Laboratories Inc. | $29.7M | $31.4M | $36.7M |
| Basic earnings per share | $1 | $1 | $1 |
| Basic earnings per share attributable to Core Laboratories Inc. | $0.64 | $0.67 | $0.79 |
| Diluted earnings per share | $1 | $1 | $1 |
| Diluted earnings per share attributable to Core Laboratories Inc. | $0.63 | $0.66 | $0.77 |
| Basic | 46.4M shares | 46.9M shares | 46.7M shares |
| Diluted | 47.0M shares | 47.7M shares | 47.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $22.7M | $19.2M | ||
| Accounts receivable, net of allowance for credit losses of $6,317 and $3,192 at 2025 and 2024, respectively | $113.5M | $111.8M | ||
| Inventories | $54.5M | $59.4M | ||
| Prepaid expenses | $9.7M | $10.2M | ||
| Income taxes receivable | $7.3M | $10.3M | ||
| Other current assets | $6.9M | $10.5M | ||
| TOTAL CURRENT ASSETS | $214.7M | $221.3M | ||
| PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $320,707 and $314,317 at 2025 and 2024, respectively | $99.4M | $97.1M | $99.6M | |
| RIGHT OF USE ASSETS | $54.3M | $56.5M | ||
| INTANGIBLES, net of accumulated amortization and impairment of $19,531 and $19,326 at 2025 and 2024, respectively | $7.1M | $6.4M | ||
| GOODWILL | $105.8M | $99.4M | $99.4M | |
| DEFERRED TAX ASSETS, net | $67.4M | $69.6M | ||
| OTHER ASSETS | $35.3M | $34.8M | ||
| TOTAL ASSETS | $584.0M | $585.1M | $586.4M | |
| Accounts payable | $37.3M | $34.5M | ||
| Accrued payroll and related costs | $26.5M | $22.9M | ||
| Taxes other than payroll and income | $4.3M | $7.1M | ||
| Unearned revenues | $5.6M | $9.3M | ||
| Operating lease liabilities | $11.5M | $10.7M | ||
| Income taxes payable | $4.3M | $9.7M | ||
| Other current liabilities | $16.7M | $8.2M | ||
| TOTAL CURRENT LIABILITIES | $106.0M | $102.4M | ||
| LONG-TERM DEBT, net | $110.3M | $126.1M | ||
| LONG-TERM OPERATING LEASE LIABILITIES | $42.3M | $43.3M | ||
| DEFERRED COMPENSATION | $29.4M | $31.1M | ||
| DEFERRED TAX LIABILITIES, net | $8.0M | $9.1M | ||
| OTHER LONG-TERM LIABILITIES | $15.8M | $20.7M | ||
| Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding | $0 | $0 | ||
| Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 46,095,379 outstanding at 2025; 46,966,868 issued and 46,826,820 outstanding at 2024 | $470.0K | $470.0K | ||
| Additional paid-in capital | $110.2M | $109.5M | ||
| Retained earnings | $172.7M | $144.9M | ||
| Accumulated other comprehensive income (loss) | -$5.8M | -$5.8M | ||
| Treasury stock (at cost), 871,489 and 140,048 at 2025 and 2024, respectively | -$11.6M | -$2.5M | ||
| Total Core Laboratories Inc. shareholders' equity | $266.0M | $246.6M | ||
| Non-controlling interest | $6.2M | $5.7M | ||
| TOTAL EQUITY | $272.2M | $252.3M | $224.4M | $183.5M |
| TOTAL LIABILITIES AND EQUITY | $584.0M | $585.1M | ||
| Allowance for doubtful accounts | $6.3M | $3.2M | ||
| Accumulated Depreciation | $320.7M | $314.3M | ||
| Accumulated amortization | $19.5M | $19.3M | ||
| Preferred stock, par value per share | $0.01 | $0.01 | ||
| Preferred stock, shares authorized | 6.0M shares | 6.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value per share | $0.01 | $0.01 | ||
| Common stock, shares authorized | 200.0M shares | 200.0M shares | ||
| Common stock, shares, issued | 47.0M shares | 47.0M shares | ||
| Common shares, outstanding | 46.1M shares | 46.8M shares | ||
| Treasury stock (at cost) | 871.5K shares | 140.0K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $22.7M | $19.2M | ||
| Accounts receivable, net of allowance for credit losses of $6,317 and $3,192 at 2025 and 2024, respectively | $113.5M | $111.8M | ||
| Inventories | $54.5M | $59.4M | ||
| Prepaid expenses | $9.7M | $10.2M | ||
| Income taxes receivable | $7.3M | $10.3M | ||
| Other current assets | $6.9M | $10.5M | ||
| TOTAL CURRENT ASSETS | $214.7M | $221.3M | ||
| PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $320,707 and $314,317 at 2025 and 2024, respectively | $99.4M | $97.1M | $99.6M | |
| RIGHT OF USE ASSETS | $54.3M | $56.5M | ||
| INTANGIBLES, net of accumulated amortization and impairment of $19,531 and $19,326 at 2025 and 2024, respectively | $7.1M | $6.4M | ||
| GOODWILL | $105.8M | $99.4M | $99.4M | |
| DEFERRED TAX ASSETS, net | $67.4M | $69.6M | ||
| OTHER ASSETS | $35.3M | $34.8M | ||
| TOTAL ASSETS | $584.0M | $585.1M | $586.4M | |
| Accounts payable | $37.3M | $34.5M | ||
| Accrued payroll and related costs | $26.5M | $22.9M | ||
| Taxes other than payroll and income | $4.3M | $7.1M | ||
| Unearned revenues | $5.6M | $9.3M | ||
| Operating lease liabilities | $11.5M | $10.7M | ||
| Income taxes payable | $4.3M | $9.7M | ||
| Other current liabilities | $16.7M | $8.2M | ||
| TOTAL CURRENT LIABILITIES | $106.0M | $102.4M | ||
| LONG-TERM DEBT, net | $110.3M | $126.1M | ||
| LONG-TERM OPERATING LEASE LIABILITIES | $42.3M | $43.3M | ||
| DEFERRED COMPENSATION | $29.4M | $31.1M | ||
| DEFERRED TAX LIABILITIES, net | $8.0M | $9.1M | ||
| OTHER LONG-TERM LIABILITIES | $15.8M | $20.7M | ||
| Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding | $0 | $0 | ||
| Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 46,095,379 outstanding at 2025; 46,966,868 issued and 46,826,820 outstanding at 2024 | $470.0K | $470.0K | ||
| Additional paid-in capital | $110.2M | $109.5M | ||
| Retained earnings | $172.7M | $144.9M | ||
| Accumulated other comprehensive income (loss) | -$5.8M | -$5.8M | ||
| Treasury stock (at cost), 871,489 and 140,048 at 2025 and 2024, respectively | -$11.6M | -$2.5M | ||
| Total Core Laboratories Inc. shareholders' equity | $266.0M | $246.6M | ||
| Non-controlling interest | $6.2M | $5.7M | ||
| TOTAL EQUITY | $272.2M | $252.3M | $224.4M | $183.5M |
| TOTAL LIABILITIES AND EQUITY | $584.0M | $585.1M | ||
| Allowance for doubtful accounts | $6.3M | $3.2M | ||
| Accumulated Depreciation | $320.7M | $314.3M | ||
| Accumulated amortization | $19.5M | $19.3M | ||
| Preferred stock, par value per share | $0.01 | $0.01 | ||
| Preferred stock, shares authorized | 6.0M shares | 6.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value per share | $0.01 | $0.01 | ||
| Common stock, shares authorized | 200.0M shares | 200.0M shares | ||
| Common stock, shares, issued | 47.0M shares | 47.0M shares | ||
| Common shares, outstanding | 46.1M shares | 46.8M shares | ||
| Treasury stock (at cost) | 871.5K shares | 140.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $30.4M | $32.2M | $37.0M |
| Stock-based compensation | $7.1M | $3.8M | $14.0M |
| Depreciation and amortization | $14.6M | $15.0M | $15.8M |
| Assets write-down | $34.0K | $1.1M | $1.1M |
| Inventory write-off and obsolescence | $2.3M | $2.9M | $1.7M |
| Net provision for credit losses | $3.4M | $1.2M | $179.0K |
| Changes in value of life insurance policies | -$1.9M | -$2.8M | -$5.0M |
| Deferred income taxes | $1.4M | $674.0K | -$10.8M |
| Insurance recovery on property, plant and equipment | -$6.8M | -$4.4M | $0 |
| Realization of pension obligation | $337.0K | -$33.0K | -$892.0K |
| Other non-cash items | $682.0K | -$1.0M | $406.0K |
| Accounts receivable | -$5.0M | -$3.6M | -$2.6M |
| Inventories | $2.6M | $9.4M | -$13.0M |
| Prepaid expenses and other current assets | -$1.2M | -$5.7M | $2.0M |
| Other assets | $28.0K | -$289.0K | $1.5M |
| Accounts payable | $477.0K | $519.0K | -$12.9M |
| Accrued expenses | -$2.7M | $2.5M | -$375.0K |
| Unearned revenues | -$3.8M | $4.6M | -$1.2M |
| Other liabilities | -$5.1M | $460.0K | -$2.2M |
| Net cash provided by operating activities | $37.0M | $56.4M | $24.8M |
| Capital expenditures - operations | -$11.2M | -$11.9M | -$10.6M |
| Capital expenditures - rebuilding of Aberdeen facility | -$3.4M | -$1.1M | $0 |
| Proceeds from insurance recovery - Aberdeen facility | $10.0M | $2.1M | $0 |
| Proceeds from sale of assets | $3.0M | $1.7M | $485.0K |
| Patents and other intangibles | -$150.0K | $20.0K | $67.0K |
| Acquisitions, net of cash acquired | -$1.2M | $0 | $0 |
| Net proceeds on life insurance policies | $778.0K | $2.8M | $3.4M |
| Net cash used in investing activities | -$2.2M | -$6.4M | -$6.7M |
| Repayment of long-term debt | -$63.0M | -$82.0M | -$211.0M |
| Proceeds from long-term debt | $48.0M | $44.0M | $202.0M |
| Debt issuance costs | -$1.7M | -$19.0K | -$1.3M |
| Equity related transaction costs | $0 | -$756.0K | -$4.1M |
| Dividends paid | -$1.9M | -$1.9M | -$1.9M |
| Repurchase of common stock | -$12.4M | -$5.3M | -$2.2M |
| Other financing activities | -$254.0K | $0 | -$54.0K |
| Net cash used in financing activities | -$31.3M | -$46.0M | -$18.4M |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | $3.5M | $4.0M | -$308.0K |
| Cash payments for interest | $8.2M | $10.9M | $11.2M |
| Cash payments for income taxes | $18.7M | $17.6M | $14.5M |
| Restricted shares withheld from employees for settlement of tax liabilities | $3.1M | $0 | $0 |
| Business acquisition contingent cash consideration | $4.1M | $0 | $0 |
| Capital expenditures incurred but not paid for as of the end of the year | $1.5M | $1.7M | $963.0K |
| Equity related transaction costs incurred but not paid for as of the end of the year | $0 | $0 | $756.0K |
No quarter-by-quarter statement was filed.
The company’s specialties include basic rock properties, special core analysis, and PVT characterization of reservoir fluids. The company is a publicly traded company on NYSE under the symbol "CLB" and was founded in 1936. It is classified in the GCIS Sub-Industry: Oil & Gas Equipment & Services.
From Wikipedia’s article on Core Laboratories, shared under CC BY-SA 4.0.7
Who has led Core Laboratories, and when. Pick a name to see everywhere that person has worked.
183 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 26 major events, 80 insider forms, 23 large holders, 41 other. The latest 20:
The 183 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Bruno LawrenceChairman and CEO | Buy | 5,000 | $10.78 | $53.9K | Form 4 |
From Forms 4 filed with the SEC.
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Ariel Investments, LLC | 14,074,945 | $164.0M | 1.6% | +904,557 |
| BlackRock, Inc. | 7,460,118 | $86.9M | 0.0% | +251,615 |
| Disciplined Growth Investors Inc /mn | 3,042,177 | $35.4M | 0.6% | −1,894,938 |
| Earnest Partners LLC | 2,941,004 | $34.3M | 0.1% | −114,992 |
| State Street Corp | 2,176,480 | $25.4M | 0.0% | +115,943 |
| CWA Asset Management Group, LLC | 1,755,085 | $20.4M | 0.6% | +14,084 |
| Vanguard Capital Management LLC | 1,590,521 | $18.5M | 0.0% | −29,342 |
| Dimensional Fund Advisors LP | 1,548,203 | $18.0M | 0.0% | +195,874 |
| Schroder Investment Management Group | 1,543,638 | $16.9M | 0.0% | New |
| Vanguard Portfolio Management LLC | 1,275,421 | $14.9M | 0.0% | +20,585 |
| Geode Capital Management, LLC | 1,193,824 | $13.9M | 0.0% | +55,866 |
| Gendell Jeffrey L | 1,090,973 | $12.7M | 0.1% | +442,513 |
| Heartland Advisors Inc | 1,058,311 | $12.3M | 0.5% | +908,311 |
| Goldman Sachs Group Inc | 751,643 | $8.8M | 0.0% | −97,258 |
| Evergreen Capital Management LLC | 669,508 | $7.8M | 0.1% | New |
| Morgan Stanley | 656,146 | $7.6M | 0.0% | +209,364 |
| Northern Trust Corp | 608,202 | $7.1M | 0.0% | +42,916 |
| Charles Schwab Investment Management Inc | 565,065 | $6.6M | 0.0% | −121,885 |
| UBS Group AG | 461,777 | $5.4M | 0.0% | +30,124 |
| Fisher Asset Management, LLC | 447,949 | $5.2M | 0.0% | −288,798 |
| Bank of New York Mellon Corp | 401,283 | $4.7M | 0.0% | −1,801 |
| Van Eck Associates Corp | 393,682 | $4.6M | 0.0% | −78,784 |
| Citadel Advisors LLC | 371,615 | $4.3M | 0.0% | +216,815 |
| Vanguard Fiduciary Trust Co | 296,584 | $3.5M | 0.0% | +7,022 |
| Principal Financial Group Inc | 272,191 | $3.2M | 0.0% | +370 |
13F reports cover disclosed long positions in U.S. stocks only.
The numbers on this page point here. Each one links to the record it came from.
